GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (STU:23I) » Definitions » Deferred Policy Acquisition Costs

Intra-Cellular Therapies (STU:23I) Deferred Policy Acquisition Costs


View and export this data going back to 2015. Start your Free Trial

What is Intra-Cellular Therapies Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Intra-Cellular Therapies (STU:23I) Business Description

Traded in Other Exchanges
Address
430 East 29th Street, New York, NY, USA, 10016
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.